Rabizn-L

Description

Rabizn-L is a combination formulation containing Rabeprazole 20 mg and Levosulpiride 75 mg in a sustained-release presentation, as specified in the supplied product details. Rabeprazole reduces stomach acid production, while levosulpiride affects dopamine receptors and gastrointestinal motility.

Healthcare professionals may prescribe this combination for selected patients with acid-related symptoms and certain gastrointestinal motility disorders. Treatment suitability depends on the patient’s diagnosis, medical history, other medicines, and the approved product information.

Therapeutic Segment

Primary Segment: Gastrointestinal Care
Related Segment: Gastroenterology and Digestive Health

Rabizn-L may be relevant to general medical practice. Its use in gynaecological or orthopaedic settings should depend on a specific clinical indication rather than the specialty alone.

Uses of Rabizn-L

A healthcare professional may consider Rabizn-L for selected gastrointestinal symptoms, such as:

• Acid-related indigestion.
• Gastro-oesophageal reflux symptoms, where the combination is clinically appropriate.
• Functional dyspepsia associated with upper abdominal discomfort or post-meal fullness.
• Certain gastrointestinal motility-related symptoms when levosulpiride is considered suitable.

The combination is not appropriate for every cause of acidity or indigestion. Persistent or unexplained symptoms require medical assessment.

Key Benefits

• Acid suppression: Rabeprazole helps reduce stomach acid secretion.
• Gastrointestinal effects: Levosulpiride may influence gastrointestinal motility and related symptoms.
• Complementary actions: The ingredients work through different mechanisms and may be prescribed together for selected patients.
• Modified-release presentation: The stated sustained-release component is intended to provide extended drug release, subject to confirmation of the approved formulation.

Individual benefits vary. The combination does not guarantee symptom relief and should be used only when both ingredients are appropriate.

How Rabizn-L Works

Rabeprazole 20 mg: Rabeprazole belongs to the proton pump inhibitor (PPI) class. It suppresses stomach acid production by inhibiting the gastric proton pumps responsible for acid secretion.

Levosulpiride 75 mg: Levosulpiride acts primarily as a dopamine D2 receptor antagonist. At certain doses, it may influence gastrointestinal motility and symptoms associated with functional digestive disorders. It can also affect prolactin levels and the central nervous system.

Together, the ingredients address acid secretion and selected gastrointestinal symptoms through different mechanisms. The exact release profile and administration instructions must follow the approved product label.

Possible Side Effects

Potential side effects may include:

• Nausea or abdominal discomfort.
• Diarrhoea or constipation.
• Headache or dizziness.
• Drowsiness or restlessness.
• Hormonal changes associated with increased prolactin, including menstrual irregularities, breast tenderness, or breast milk production.

Levosulpiride can cause serious neurological adverse effects, including movement disorders, and may affect heart rhythm in susceptible patients. Seek urgent medical care for fainting, palpitations with dizziness, severe muscle stiffness, unusual involuntary movements, or a severe allergic reaction.

Important Safety Information

• Use Rabizn-L only under the supervision of a qualified healthcare professional.
• Levosulpiride may cause drowsiness or dizziness. Avoid driving or operating machinery if affected.
• Tell the prescriber about any history of movement disorders, seizures, heart rhythm problems, or conditions associated with elevated prolactin.
• Levosulpiride may be unsuitable in certain conditions involving gastrointestinal bleeding, obstruction, or perforation, where increased gastrointestinal movement could be harmful.
• Inform the prescriber about all medicines being taken, particularly medicines that cause sedation or may affect heart rhythm.
• Rabeprazole can interact with certain medicines, including some whose absorption depends on stomach acidity.
• Persistent vomiting, difficulty swallowing, unexplained weight loss, blood in vomit or stools, or severe abdominal pain requires prompt medical evaluation.
• Long-term use should be reviewed regularly to assess ongoing need and potential adverse effects.

Dosage and Administration

Take Rabizn-L only as prescribed and follow the approved product label. The appropriate dose, timing, and duration depend on the patient’s condition and the exact formulation.

Do not crush, chew, open, or alter a sustained-release dosage unit unless the approved instructions explicitly permit it. Do not increase the dose or extend treatment without consulting the prescriber.

Product verification required: Confirm whether the stated 75 mg levosulpiride strength is the sustained-release strength of the finished product and verify the dosage form and release specifications against the approved product documentation.

Storage Instructions

Store Rabizn-L according to the instructions printed on its approved packaging. Keep it in its original Alu-Alu blister, protected from excessive heat and moisture, and out of children’s reach. Do not use it after its expiry date or if the packaging is damaged.